



120

D102-04

RCE/1600
44

PTO/SB/30 (09-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

RECEIVED

JAN 9 2004

TECH CENTER 1600/2900

**Request
For
Continued Examination (RCE)
Transmittal**

Address to:
MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

<i>Application Number</i>	08/279,275
<i>Filing Date</i>	July 22, 1994
<i>First Named Inventor</i>	Howard L. Weiner
<i>Art Unit</i>	1644
<i>Examiner Name</i>	Ewoldt, Gerald R.
<i>Attorney Docket No.</i>	01010/1006104-US4

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).
 - a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.
 - i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
 - ii. Other _____
 - b. Enclosed
 - i. Amendment/Reply
 - ii. Affidavit(s)/Declaration(s)
 - iii. Information Disclosure Statement (IDS)
 - iv. Other _____
2. **Miscellaneous**
 - a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
 - b. Other _____
3. **Fees** The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.
 - a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. _____
 - i. RCE fee required under 37 CFR 1.17(e)
 - ii. Extension of time fee (37 CFR 1.136 and 1.17)
 - iii. Other _____
 - b. Check in the amount of \$ 2,780.00 enclosed
 - c. Payment by credit card (Form PTO-2038 enclosed)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Sandra S. Lee	Registration No. (Attorney/Agent)	51,932
Signature	<i>Sandra Lee</i>	Date	December 31, 2003

01/05/2004 CCHAU1 0000060 08279275

01 FC:1801

770.00 OP

Express Mail Label No.

Dated: _____



EXPRESS MAIL CERTIFICATE

Date _____ Label No. _____
I hereby certify that, on the date indicated above, this paper or
fee was deposited with the U.S. Postal Service & that it was
addressed for delivery to the Commissioner for Patents, PO
Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post
Office to Addressee" service.

Name (Print) _____ Signature _____

Customer No.: 07278

Docket No: 01010/1006104-US4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Howard L. Weiner et. Al.

Serial No.: 08/279,275

Art Unit: 1644

Confirmation No.: 7626

Filed: July 22, 1994

Examiner: Ewoldt, Gerald R.

For: TREATMENT OF AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF
AUTOANTIGENS

RESPONSE TO OFFICIAL ACTION

Commissioner of
Patents and Trademarks
Alexandria, VA 22313-1450

December 31, 2003

Sir:

In response to the Official Action dated December 2, 2002, please amend the
above-identified application as follows.

Amendments to the claims are reflected in the listing of claims which begins
on page 2 of this paper.

Amendments to the specification begin on page 5 of this paper.

Remarks begin on page 6 of this paper.